Bernard-Soulier syndrome Medical Services in China

Bernard-Soulier syndrome (BSS) is a rare, inherited bleeding disorder caused by defects in the platelet glycoprotein Ib-IX-V complex — a critical receptor for von Willebrand factor (VWF) that mediates platelet adhesion to damaged vascular subendothelium. This autosomal recessive condition results in thrombocytopenia (low platelet count), abnormally large platelets (macrothrombocytes), and impaired platelet function, leading to prolonged bleeding time despite normal coagulation factor levels. Pathogenically, mutations in any of three genes — GP1BA, GP1BB, or GP9 — disrupt assembly or surface expression of the GPIb-IX-V complex, compromising the initial tethering step of hemostasis. As a consequence, patients exhibit mucocutaneous bleeding manifestations including easy bruising, epistaxis, gingival bleeding, menorrhagia, and prolonged bleeding after minor trauma or surgery. Severe cases may involve gastrointestinal or postpartum hemorrhage, though spontaneous intracranial or visceral bleeding is uncommon. Epidemiologically, BSS is extremely rare, with an estimated prevalence of 1 in 1 million individuals worldwide; fewer than 200 well-documented cases have been reported in the literature. It affects males and females equally and shows no ethnic predilection, though consanguinity significantly increases risk due to its autosomal recessive inheritance pattern. Risk factors include parental consanguinity, family history of unexplained bleeding or thrombocytopenia, and recurrent childhood hemorrhagic episodes misdiagnosed as immune thrombocytopenia (ITP). Quality of life impact is substantial: patients often experience anxiety around injury or invasive procedures, limitations in physical activity and sports participation, school or work absenteeism due to bleeding episodes or medical appointments, and psychosocial burden related to chronic disease management and reproductive concerns (e.g., menorrhagia, pregnancy-related hemorrhage risk). While not life-threatening in most cases with appropriate care, untreated or mismanaged BSS can lead to severe anemia, transfusion dependence, iron deficiency, and rare but catastrophic hemorrhage. Lifelong monitoring by a hematologist is essential, and patient education on bleeding avoidance, emergency protocols, and genetic counseling is integral to comprehensive care.

Bernard-Soulier syndrome (BSS) is a rare, autosomal recessive inherited bleeding disorder characterized by defective platelet adhesion due to quantitative or qualitative abnormalities of the GPIa/IIa (GPIa-2b/3a) complex—more accurately termed the GPIb-IX-V complex. This transmembrane receptor complex mediates the initial tethering of platelets to von Willebrand factor (VWF) anchored at sites of vascular injury under high shear stress, particularly in arterioles and capillaries. The primary cause of BSS is biallelic pathogenic variants in one of three genes: GP1BA (encoding GPIbα), GP1BB (encoding GPIbβ), or GP9 (encoding GPIX). Mutations in GP1BA account for approximately 60% of genetically confirmed cases; GP1BB and GP9 mutations each account for ~20%. These variants lead to absent, markedly reduced, or dysfunctional expression of the entire GPIb-IX-V complex on the platelet surface, resulting in macrothrombocytopenia (giant platelets and low platelet counts) and prolonged bleeding time. No acquired (non-genetic) form of classic BSS exists; however, rare cases of acquired GPIb-IX-V deficiency have been reported in association with lymphoproliferative disorders (e.g., chronic lymphocytic leukemia), autoimmune conditions (e.g., anti-GPIb antibodies in immune thrombocytopenia), or following allogeneic hematopoietic stem cell transplantation—these represent phenocopies rather than true BSS and lack the characteristic genetic basis and lifelong presentation. Triggers of clinical hemorrhage in BSS are typically physiological or iatrogenic stressors that challenge hemostasis: mucocutaneous trauma (e.g., dental procedures, epistaxis, menorrhagia), surgical interventions, childbirth, gastrointestinal erosions, or concomitant use of antiplatelet agents (e.g., aspirin, NSAIDs) or anticoagulants. Viral infections—particularly those causing transient thrombocytopenia or endothelial activation—may exacerbate bleeding diathesis. Risk factors for severe bleeding manifestations include profound thrombocytopenia (<30 × 10⁹/L), large platelet size (>5 fL mean platelet volume), undiagnosed or untreated disease, absence of prophylactic management prior to invasive procedures, and co-inheritance of other hemostatic defects (e.g., mild von Willebrand disease or factor deficiencies). Genetic factors are central: BSS follows strict autosomal recessive inheritance; thus, affected individuals inherit one pathogenic variant from each asymptomatic carrier parent. Consanguinity significantly increases recurrence risk (25% per pregnancy). Founder mutations have been identified in specific populations—e.g., a GP1BB c.485_486delAG variant in French Canadians, and recurrent GP9 variants in Japanese cohorts—contributing to higher prevalence in geographically or ethnically isolated groups. Environmental factors do not cause BSS but modulate its clinical expression. Chronic exposure to nonsteroidal anti-inflammatory drugs (NSAIDs) or herbal supplements with antiplatelet activity (e.g., ginkgo biloba, garlic) heightens bleeding risk. Poor oral hygiene predisposes to gingival bleeding and periodontitis-related hemorrhage. High-altitude residence may theoretically increase shear stress on platelets, though clinical evidence is lacking. Nutritional deficiencies (e.g., vitamin C deficiency causing scurvy-like capillary fragility) or uncontrolled hypertension can synergistically impair microvascular integrity, worsening mucocutaneous bleeding. Importantly, no environmental exposures induce the genetic defect or initiate disease onset—BSS is present from birth, though diagnosis is often delayed until infancy or childhood following abnormal umbilical stump bleeding, excessive bruising, or post-circumcision hemorrhage. Prenatal diagnosis is feasible via chorionic villus sampling or amniocentesis when familial variants are known. Genetic counseling is essential for at-risk families, emphasizing carrier testing, reproductive options, and avoidance of unnecessary platelet transfusions (which may induce alloantibodies). Overall, BSS exemplifies a molecularly defined platelet adhesion defect wherein genotype–phenotype correlations exist but remain imperfect; disease severity varies even among individuals with identical mutations, suggesting roles for modifier genes and epigenetic or stochastic factors in clinical expressivity.

Bernard-Soulier syndrome (BSS) is a rare, autosomal recessive inherited platelet function disorder characterized by defective platelet adhesion due to quantitative or qualitative abnormalities of the GPIa/IIa (GPIa–IIa) complex—more accurately designated the GPIa–IIa integrin receptor, though historically misattributed to GPIb–IX–V. In fact, BSS results from pathogenic variants in one of three genes: GP1BA (encoding GPIbα), GP1BB (encoding GPIbβ), or GP9 (encoding GPIX), all components of the GPIb–IX–V receptor complex essential for von Willebrand factor (VWF)-mediated platelet tethering to subendothelial collagen at sites of vascular injury. The hallmark laboratory finding is macrothrombocytopenia—markedly enlarged (giant) platelets with profound thrombocytopenia—alongside prolonged bleeding time and impaired ristocetin-induced platelet aggregation (RIPA), which fails to correct with added normal plasma but responds to exogenous VWF. Clinically, symptoms typically manifest in infancy or early childhood, although milder cases may remain undiagnosed until adolescence or adulthood following hemostatic challenges such as surgery, dental extractions, or menarche.

Early symptoms are predominantly mucocutaneous and often appear within the first year of life. Neonates may present with umbilical stump bleeding, cephalohematoma, or postcircumcision hemorrhage. Infants frequently exhibit easy bruising (ecchymoses), recurrent epistaxis, and prolonged bleeding after minor trauma or immunizations. Oral manifestations include gingival bleeding during teething or routine dental hygiene. Petechiae—small, non-blanching, 1–2 mm hemorrhagic spots—are common on the lower extremities and pressure areas, reflecting capillary fragility secondary to ineffective primary hemostasis. Parents may report excessive oozing from minor lacerations or prolonged bleeding after heel sticks or venipuncture.

Typical symptoms reflect chronic, lifelong impairment of primary hemostasis. Patients experience recurrent, spontaneous, or trauma-induced mucocutaneous bleeding: epistaxis episodes lasting >10 minutes and requiring nasal packing in ~70% of affected individuals; menorrhagia in postpubertal females, often leading to iron-deficiency anemia and requiring hormonal or antifibrinolytic therapy; gastrointestinal bleeding (e.g., melena, hematemesis) due to angiodysplasia or erosive gastritis exacerbated by platelet dysfunction; and postpartum hemorrhage. Hematuria—usually microscopic but occasionally gross—is observed in ~20–30% of patients, particularly after urinary tract instrumentation. Unlike hemophilia, BSS does not cause deep tissue hematomas, hemarthroses, or muscle bleeds, as these require coagulation factor–dependent thrombin generation and stable fibrin clot formation, which remains intact in BSS.

Accompanying symptoms include fatigue and pallor secondary to chronic blood loss and iron-deficiency anemia, especially in menstruating women or those with occult GI bleeding. Some patients develop mild splenomegaly, likely reactive rather than infiltrative, though its clinical significance remains unclear. Thrombocytopenia-related symptoms such as headache or dizziness are uncommon unless platelet counts fall below 20 × 10⁹/L; however, bleeding risk does not correlate linearly with platelet count due to the functional defect—patients with counts as low as 10–30 × 10⁹/L may remain asymptomatic, whereas others with counts >50 × 10⁹/L bleed readily. Notably, platelet size inversely correlates with bleeding severity in some cohorts, suggesting that giant platelets retain partial adhesive capacity.

Complications arise primarily from uncontrolled hemorrhage or iatrogenic interventions. Life-threatening complications include intracranial hemorrhage (rare but reported), massive epistaxis requiring embolization or septal surgery, and postoperative bleeding necessitating re-exploration. Chronic menorrhagia predisposes to severe iron-deficiency anemia, requiring intravenous iron or transfusion support. Repeated red blood cell transfusions carry risks of alloimmunization, iron overload, and transfusion-transmitted infections. Platelet transfusions—though lifesaving in acute hemorrhage or preoperative prophylaxis—may induce alloantibodies against GPIb–IX–V, rendering subsequent transfusions ineffective and increasing risk of refractoriness. Splenectomy is generally contraindicated due to lack of efficacy and heightened risk of overwhelming sepsis and thrombosis. Pregnancy poses elevated maternal hemorrhage risk, particularly during delivery and the puerperium; neuraxial anesthesia is relatively contraindicated due to spinal hematoma risk.

Diagnosis relies on integration of clinical history, peripheral blood smear morphology, and specialized platelet function testing. Complete blood count reveals isolated thrombocytopenia (platelet count typically 20–100 × 10⁹/L) with markedly increased mean platelet volume (MPV > 12 fL, often >15 fL). Peripheral smear demonstrates characteristic giant platelets (>4 µm, sometimes >8 µm), comprising >5% of total platelets, alongside normal erythrocyte and leukocyte morphology. Prothrombin time (PT), activated partial thromboplastin time (aPTT), and fibrinogen are invariably normal. Bleeding time is prolonged (>12 minutes), though this test is largely obsolete. Definitive diagnosis requires flow cytometry demonstrating reduced or absent surface expression of GPIbα, GPIbβ, or GPIX; monoclonal antibody–specific immobilization of platelet antigens (MAIPA) assay further characterizes epitope-specific defects. Ristocetin cofactor activity (VWF:RCo) and plasma VWF antigen (VWF:Ag) are normal, distinguishing BSS from von Willebrand disease (VWD). Genetic testing confirms biallelic pathogenic variants in GP1BA, GP1BB, or GP9.

Differential diagnosis includes other inherited macrothrombocytopenias: MYH9-related disorders (e.g., May–Hegglin anomaly), which feature Döhle-like leukocyte inclusions and progressive sensorineural deafness, nephropathy, and cataracts; gray platelet syndrome (GPS), characterized by alpha-granule deficiency, normal platelet size, and mild thrombocytopenia; and ANKRD26- or ETV6-related thrombocytopenias, which lack giant platelets. Acquired conditions must also be excluded: immune thrombocytopenia (ITP) presents with normal platelet size and no family history; drug-induced thrombocytopenia (e.g., abciximab, tirofiban) causes transient GPIIb/IIIa blockade but no giant platelets; and myelodysplastic syndromes may show dysplastic megakaryocytes but lack consistent giant platelets or GPIb–IX–V deficiency. Pseudothrombocytopenia due to EDTA-dependent platelet agglutination mimics thrombocytopenia but shows normal platelet size and no bleeding diathesis. Crucially, BSS must be distinguished from VWD type 2B, which also exhibits enhanced ristocetin-induced platelet aggregation at low doses and thrombocytopenia—but with normal GPIb–IX–V expression and abnormal VWF multimer pattern on electrophoresis.

Bernard-Soulier syndrome (BSS) is a rare, autosomal recessive inherited bleeding disorder caused by defects in the GPIa/IIa (GPIa-2) complex—specifically, mutations in the GP1BA, GP1BB, or GP9 genes—resulting in deficient or dysfunctional platelet glycoprotein Ib-IX-V receptor. This receptor is essential for platelet adhesion to von Willebrand factor (VWF) at sites of vascular injury, leading to impaired primary hemostasis. Patients present with mucocutaneous bleeding (e.g., epistaxis, gingival bleeding, menorrhagia), prolonged bleeding time, thrombocytopenia, and abnormally large platelets (macrothrombocytes) on peripheral blood smear. Diagnosis relies on flow cytometry demonstrating reduced or absent CD42a (GPIa) and/or CD42b (GPIbα) expression, alongside genetic confirmation. Management is multidisciplinary and tailored to bleeding severity, surgical risk, and patient-specific factors.

Conservative treatment forms the cornerstone of long-term BSS management and emphasizes bleeding prevention and prompt non-invasive intervention. Patients must avoid antiplatelet agents (e.g., aspirin, NSAIDs, clopidogrel), anticoagulants unless absolutely indicated, and intramuscular injections. Comprehensive dental care—including prophylactic scaling, fluoride application, and early caries management—is critical to prevent gingival hemorrhage. Menstruating individuals benefit from hormonal therapy (e.g., combined oral contraceptives or levonorgestrel-releasing intrauterine systems) to reduce menstrual blood loss. Iron supplementation is routinely prescribed for chronic iron-deficiency anemia secondary to recurrent bleeding. Education on recognizing early signs of hemorrhage (e.g., prolonged oozing after minor trauma, petechiae, hematuria) and accessing emergency care is integral. Regular hematologic monitoring—including complete blood count, platelet count, and bleeding time assessment when clinically indicated—is recommended every 6–12 months in stable patients.

Pharmacologic interventions are limited due to the intrinsic platelet defect; however, several agents play adjunctive roles. Desmopressin (DDAVP) may transiently improve hemostasis in some BSS patients by promoting endothelial release of VWF and enhancing platelet–endothelium interaction, though response is variable and often suboptimal compared to other platelet disorders. Antifibrinolytics—particularly tranexamic acid—are highly effective for mucosal bleeding (e.g., epistaxis, dental procedures, menorrhagia) and are considered first-line medical therapy for acute or prophylactic use. Tranexamic acid inhibits plasminogen activation, thereby stabilizing clots formed despite defective platelet adhesion. It is administered orally (1–1.5 g three times daily) or intravenously (10 mg/kg bolus followed by 1 mg/kg/h infusion) perioperatively or during active bleeding. Recombinant activated factor VII (rFVIIa) has demonstrated efficacy in refractory bleeding episodes and major surgery, acting independently of platelet GPIb-IX-V by directly activating thrombin generation on tissue factor-expressing cells. However, its use is reserved for life-threatening hemorrhage or high-risk procedures due to cost, thrombotic risk, and lack of long-term safety data in BSS.

Surgical treatment is rarely curative but may be necessary in specific contexts. Splenectomy is contraindicated in BSS—not only because it fails to correct the underlying platelet defect but also because it increases the risk of overwhelming post-splenectomy infection (OPSI) and thrombosis without improving platelet counts or function. Hematopoietic stem cell transplantation (HSCT) remains the only potentially curative modality, but it is reserved for severe, transfusion-dependent cases with matched sibling donors due to substantial morbidity, mortality, and graft-versus-host disease risk. In China, HSCT protocols have evolved with improved HLA-typing accuracy, reduced-intensity conditioning regimens, and enhanced supportive care, yielding 5-year overall survival rates exceeding 85% in pediatric BSS patients undergoing matched sibling donor transplants. Gene therapy remains investigational, with preclinical studies targeting GP1BA correction in autologous CD34+ cells showing promising in vitro platelet functional restoration.

Treatment advantages in China include centralized expertise through national bleeding disorder centers affiliated with top-tier hospitals (e.g., Peking Union Medical College Hospital, Shanghai Ruijin Hospital), where multidisciplinary teams integrate hematology, transfusion medicine, obstetrics, dentistry, and genetics. China’s National Hemophilia Treatment Network ensures standardized diagnostic algorithms, including rapid-access flow cytometry and next-generation sequencing panels for GP1BA/GP1BB/GP9 analysis. The domestic production of high-purity tranexamic acid and rFVIIa (e.g., NovoSeven® biosimilars approved by the NMPA) significantly reduces treatment costs—up to 40% lower than imported equivalents—enhancing accessibility. Moreover, China’s robust blood bank infrastructure supports timely access to HLA-matched platelet transfusions, which remain the mainstay for perioperative hemostasis and life-threatening bleeding. Platelet transfusions, while effective acutely, require careful management to mitigate alloimmunization; Chinese centers employ extended HLA and HPA typing and implement platelet refractoriness protocols using crossmatch-compatible units.

Recovery and long-term prognosis hinge on proactive, individualized care. Patients should maintain a hemoglobin level >11 g/dL and ferritin >50 ng/mL to support erythropoiesis and minimize fatigue. Physical activity should be encouraged but modified to avoid contact sports and high-impact trauma; swimming and cycling are preferred. Vaccination adherence—including pneumococcal, meningococcal, and Haemophilus influenzae type b vaccines—is mandatory, especially for splenectomized or immunosuppressed individuals. Psychological support is vital: chronic bleeding disorders correlate with elevated anxiety and depression prevalence, and Chinese tertiary centers increasingly embed clinical psychologists within hemophilia/BSS clinics. Women of childbearing age require preconception counseling regarding inheritance risk (25% recurrence with consanguineous partners), fetal genotyping options (CVS/amniocentesis), and peripartum hemostatic planning—including neuraxial anesthesia avoidance and scheduled cesarean delivery with tranexamic acid and platelet coverage. With comprehensive care, most BSS patients achieve near-normal life expectancy and quality of life. Mortality remains primarily associated with intracranial hemorrhage, uncontrolled postpartum bleeding, or complications of invasive procedures—underscoring the necessity of coordinated, protocol-driven management across the continuum of care.